Premium
[P1–239]: DEVELOPMENT OF A NOVEL MULTI‐BIOMARKER ASSESSMENT SCORE FOR ALZHEIMER's DISEASE
Author(s) -
Weber Darren M.,
Goldman Scott,
Clarke Nigel,
Lagier Robert,
Rissman Robert A.,
Rowland Charles,
Ginns Edward I.,
Brewer James B.
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.059
Subject(s) - biomarker , logistic regression , apolipoprotein e , medicine , likelihood ratios in diagnostic testing , cohort , disease , neuropathology , oncology , alzheimer's disease neuroimaging initiative , proportional hazards model , cerebrospinal fluid , alzheimer's disease , confidence interval , biology , biochemistry
TDP had lower levels of sAPPb and higher levels of YKL-40 in CSF compared to controls (Fig. 1). The sAPPb/YKL-40 ratio was lower in both FTLD groups compared to controls. In the ROC analysis (Fig. 2), the sAPPb/YKL-40 ratio had an area under the curve of 0.91 (95%CI 0.86-0.96) to distinguish FTLD subjects from controls, but lower values to distinguish FTLD from AD (AUC 0.70; 95%CI 0.61-0.79) and to discriminate FTLDTau from FTLD-TDP (AUC 0.67; 95%CI 0.51-0.82). Conclusions:These findings suggest that the sAPPb/YKL-40 ratio could be of interest to distinguish patients with FTLD from those with similar clinical phenotypes. Although the ratio cannot be used to discriminate between the main pathologies underlying FTLD, it might be useful to interrogate the neuropathological substrate in some clinical scenarios and, eventually, to select potential candidates for clinical trials.